Telix Pharmaceuticals Limited(TLX)Earnings, Financials & Key Ratios
TLX•NASDAQ
$10.66
$3.57B mkt cap·105.1× P/E·Price updated May 7, 2026
AboutTelix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.Show more
- Revenue$783M+55.8%
- EBITDA$88M+49.8%
- Net Income$50M+858.0%
- EPS (Diluted)0.14+769.6%
- Gross Margin65.08%+4.0%
- EBITDA Margin11.21%-3.9%
- Operating Margin10.49%+1.6%
- Net Margin6.37%+514.7%
- ROE13.92%+205.8%
- ROIC25.54%-94.3%
- Debt/Equity1.02+773.5%
- Interest Coverage3.83
TLX Key Insights
Telix Pharmaceuticals Limited (TLX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 83 (top 17%)
- ✓Strong 5Y sales CAGR of 195.3%
✗Weaknesses
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TLX Price & Volume
Telix Pharmaceuticals Limited (TLX) stock price & volume — 10-year historical chart
Loading chart...
TLX Growth Metrics
Telix Pharmaceuticals Limited (TLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years195.35%
3 Years368.92%
TTM329.97%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM139.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM135.46%
Return on Capital
10 Years-30.99%
5 Years-31.67%
3 Years-12.67%
Last Year11.52%
TLX Recent Earnings
Telix Pharmaceuticals Limited (TLX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 0/12 qtrs (0%)●Beat Revenue 5/12 qtrs (56%)
Q1 2026Latest
Feb 19, 2026EPS
$0.01
Est $0.03
-135.4%
Revenue
$413M
Est $418M
-1.2%
Q3 2025
Aug 20, 2025EPS
$0.01
Est $0.13
-105.1%
Revenue
$389M
Est $323M
+20.4%
Q1 2025
Feb 20, 2025EPS
$0.07
Est $0.09
-25.2%
Revenue
$368M
Est $135M
+172.3%
Q3 2024
Aug 22, 2024EPS
$0.02
Est $0.09
-75.0%
Revenue
$126M
Est $238M
-47.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 19, 2026 | $0.01vs $0.03-135.4% | $413Mvs $418M-1.2% |
| Q3 2025 | Aug 20, 2025 | $0.01vs $0.13-105.1% | $389Mvs $323M+20.4% |
| Q1 2025 | Feb 20, 2025 | $0.07vs $0.09-25.2% | $368Mvs $135M+172.3% |
| Q3 2024 | Aug 22, 2024 | $0.02vs $0.09-75.0% | $126Mvs $238M-47.0% |
Based on last 12 quarters of dataView full earnings history →
TLX Peer Comparison
Telix Pharmaceuticals Limited (TLX) competitors in Radiopharmaceuticals and Targeted Radiation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXEL | 11.74B | 46.21 | 16.62 | 6.98% | 35.08% | 40.21% | 0.08 | |
 RNW | 1.33B | 5.40 | 46.91 | 19.36% | 9.23% | 8.42% | 5.59 | |
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 LNTH | 5.92B | 91.00 | 26.69 | 0.5% | 18.05% | 24.33% | 0.00 | |
 NVS | 277.42B | 145.39 | 20.22 | 5.97% | 24.14% | 31.42% | 0.80 | |
 BMY | 114.85B | 56.25 | 16.30 | -0.22% | 15.01% | 38.96% | 2.55 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 GE | 316.2B | 302.63 | 37.09 | 18.48% | 17.91% | 45.85% | 1.08 |
Compare TLX vs Peers
Telix Pharmaceuticals Limited (TLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TLX Income Statement
Telix Pharmaceuticals Limited (TLX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 195.14K | 3.48M | 5.21M | 7.6M | 160.1M | 502.55M | 783.21M | 1.66B |
| Revenue Growth % | - | - | 1685.88% | 49.58% | 45.71% | 2007.64% | 213.9% | 55.85% | 329.97% |
| Cost of Goods Sold | 3.79K | 0 | 15.36M | 22.09M | 37.36M | 130.76M | 188.16M | 273.53M | 636.04M |
| COGS % of Revenue | - | - | 440.75% | 423.75% | 491.85% | 81.68% | 37.44% | 34.92% | - |
| Gross Profit | -3.79K▲ 0% | 195.14K▲ 5244.8% | -11.88M▼ 6185.3% | -16.88M▼ 42.1% | -29.77M▼ 76.4% | 29.34M▲ 198.6% | 314.39M▲ 971.7% | 509.68M▲ 62.1% | 1.02B▲ 0% |
| Gross Margin % | - | 100% | -340.75% | -323.75% | -391.85% | 18.32% | 62.56% | 65.08% | 61.64% |
| Gross Profit Growth % | - | 5244.79% | -6185.31% | -42.12% | -76.36% | 198.56% | 971.65% | 62.12% | - |
| Operating Expenses | 6.52M | 27.85M | 28.38M | 47.56M | 81.12M | 102.52M | 263.27M | 427.55M | 904M |
| OpEx % of Revenue | - | 14271.2% | 814.38% | 912.33% | 1067.94% | 64.03% | 52.39% | 54.59% | - |
| Selling, General & Admin | 2.67M | 9.08M | 11.59M | 19.21M | 46.99M | 87.1M | 134.16M | 207.13M | 428.49M |
| SG&A % of Revenue | - | 4651.88% | 332.48% | 368.46% | 618.56% | 54.4% | 26.7% | 26.45% | - |
| Research & Development | 2.98M | 18.69M | 21.16M | 23.09M | 34.13M | 57.86M | 128.84M | 121.03M | 343.39M |
| R&D % of Revenue | - | 9578.68% | 607.23% | 442.84% | 449.38% | 36.14% | 25.64% | 15.45% | - |
| Other Operating Expenses | 112.64K | 0 | -4.37M | 5.27M | 0 | -42.44M | 270K | 99.39M | 2.1M |
| Operating Income | -6.37M▲ 0% | -15.68M▼ 146.3% | -40.26M▼ 156.7% | -49.25M▼ 22.3% | -81.25M▼ 65.0% | -91.93M▼ 13.1% | 51.89M▲ 156.4% | 82.13M▲ 58.3% | 117.99M▲ 0% |
| Operating Margin % | - | -8037.67% | -1155.12% | -944.81% | -1069.6% | -57.42% | 10.32% | 10.49% | 7.12% |
| Operating Income Growth % | - | -146.32% | -156.65% | -22.35% | -64.96% | -13.15% | 156.44% | 58.29% | - |
| EBITDA | -6.36M | -15.68M | -36.02M | -44.94M | -76.07M | -86.55M | 58.63M | 87.82M | 132.42M |
| EBITDA Margin % | - | -8034.12% | -1033.57% | -862.09% | -1001.49% | -54.06% | 11.67% | 11.21% | 7.99% |
| EBITDA Growth % | - | -146.36% | -129.75% | -24.77% | -69.27% | -13.77% | 167.74% | 49.78% | 264.77% |
| D&A (Non-Cash Add-back) | 3.79K | 6.93K | 4.24M | 4.31M | 5.17M | 5.38M | 6.74M | 5.69M | 14.42M |
| EBIT | -6.77M | -15.68M | -28.71M | -49.25M | -75.25M | -98.22M | 16.22M | 92.55M | 111.69M |
| Net Interest Income | 29.58K | 303.73K | -2.31M | -1.11M | -163K | -405K | -12.74M | -10.6M | -14.5M |
| Interest Income | 38.98K | 332.75K | 98K | 67K | 163K | 1K | 694.25K | 10.86M | 11.43M |
| Interest Expense | 9.4K | 29.02K | 2.41M | 1.18M | 189K | 406K | 13.56M | 21.46M | 25.93M |
| Other Income/Expense | 142.22K | 11.94M | 0 | -11M | -17.79M | -6.69M | 0 | -26.07M | -53.9M |
| Pretax Income | -6.38M▲ 0% | -15.71M▼ 146.4% | -42.81M▼ 172.5% | -60.25M▼ 40.7% | -99.04M▼ 64.4% | -98.62M▲ 0.4% | 3.09M▲ 103.1% | 56.06M▲ 1715.9% | 64.1M▲ 0% |
| Pretax Margin % | - | -8052.54% | -1228.55% | -1155.82% | -1303.83% | -61.6% | 0.61% | 7.16% | 3.87% |
| Income Tax | 9.4K | -1.88M | -14.95M | -15.37M | -18.53M | 5.46M | -2.12M | 6.14M | 5.86M |
| Effective Tax Rate % | -0.15% | 11.99% | 34.91% | 25.5% | 18.71% | -5.53% | -68.8% | 10.95% | 9.14% |
| Net Income | -6.38M▲ 0% | -13.83M▼ 116.9% | -27.87M▼ 101.5% | -44.89M▼ 61.1% | -80.51M▼ 79.4% | -104.08M▼ 29.3% | 5.21M▲ 105.0% | 49.92M▲ 858.0% | 65.97M▲ 0% |
| Net Margin % | - | -7087.06% | -799.63% | -861.06% | -1059.9% | -65.01% | 1.04% | 6.37% | 3.98% |
| Net Income Growth % | - | -116.87% | -101.5% | -61.08% | -79.36% | -29.27% | 105.01% | 857.95% | 139.65% |
| Net Income (Continuing) | -6.38M | -13.83M | -27.87M | -44.89M | -80.51M | -104.08M | 5.21M | 49.92M | 58.24M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.05▲ 0% | -0.07▼ 37.3% | -0.12▼ 75.4% | -0.17▼ 41.7% | -0.29▼ 70.6% | -0.34▼ 17.2% | 0.02▲ 104.7% | 0.14▲ 769.6% | 0.20▲ 0% |
| EPS Growth % | - | -37.35% | -75.44% | -41.67% | -70.59% | -17.24% | 104.74% | 769.57% | 135.46% |
| EPS (Basic) | -0.05 | -0.07 | -0.12 | -0.17 | -0.29 | -0.34 | 0.02 | 0.15 | - |
| Diluted Shares Outstanding | 127.99M | 202.12M | 233.44M | 257.27M | 282.21M | 310.64M | 323.71M | 345.19M | 337.2M |
| Basic Shares Outstanding | 127.99M | 202.12M | 233.44M | 257.27M | 282.21M | 310.64M | 319.18M | 331.23M | 337.21M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
TLX Balance Sheet
Telix Pharmaceuticals Limited (TLX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 49.55M | 35.86M | 58.68M | 93.63M | 47.54M | 173.23M | 224.85M | 918.56M | 398.01M |
| Cash & Short-Term Investments | 48.76M | 25.77M | 44.6M | 77.94M | 22.04M | 79.14M | 123.24M | 710.35M | 207.16M |
| Cash Only | 48.76M | 25.77M | 44.6M | 77.94M | 22.04M | 116.33M | 123.24M | 710.35M | 207.16M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 488.83K | 8.97M | 13.01M | 14.19M | 20.84M | 31.14M | 79.53M | 158.99M | 129.52M |
| Days Sales Outstanding | - | 16.78K | 1.36K | 993.62 | 1K | 71 | 57.77 | 74.1 | 24.8 |
| Inventory | 297.22K | 642.52K | 542K | 633K | 3.45M | 5.77M | 17.31M | 38.14M | 35.23M |
| Days Inventory Outstanding | 28.6K | - | 12.88 | 10.46 | 33.74 | 16.1 | 33.58 | 50.9 | 17.43 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 55.48M | -7.66M | 0 | 26.1M |
| Total Non-Current Assets | 1.55M | 40.85M | 43.93M | 70.81M | 62.27M | 87.36M | 173.45M | 597.87M | 791.94M |
| Property, Plant & Equipment | 5.39K | 226.17K | 1.9M | 4.82M | 6.33M | 18.84M | 30.49M | 54.32M | 74.18M |
| Fixed Asset Turnover | - | 0.86x | 1.84x | 1.08x | 1.20x | 8.50x | 16.48x | 14.42x | 33.62x |
| Goodwill | 332.49K | 3.14M | 4.22M | 4.22M | 4.1M | 5.52M | 4.85M | 106.65M | 185.81M |
| Intangible Assets | 1.18M | 36.31M | 41.95M | 59.19M | 55.73M | 58.98M | 104.82M | 309.49M | 398.36M |
| Long-Term Investments | 0 | 1.14M | 0 | -4.22M | 0 | -5.52M | 12.26M | 6.09M | 32.87M |
| Other Non-Current Assets | 35.29K | 1.17M | -4.14M | 183K | -3.88M | 327K | 586K | 74.58M | 416.46M |
| Total Assets | 51.09M▲ 0% | 76.71M▲ 50.1% | 102.61M▲ 33.8% | 157.82M▲ 53.8% | 109.81M▼ 30.4% | 260.59M▲ 137.3% | 398.3M▲ 52.8% | 1.52B▲ 280.7% | 1.19B▲ 0% |
| Asset Turnover | - | 0.00x | 0.03x | 0.03x | 0.07x | 0.61x | 1.26x | 0.52x | 1.72x |
| Asset Growth % | - | 50.13% | 33.76% | 53.81% | -30.42% | 137.3% | 52.85% | 280.72% | 533.46% |
| Total Current Liabilities | 1.47M | 8.24M | 10.63M | 19.96M | 37.98M | 85.56M | 157.41M | 330.91M | 298.58M |
| Accounts Payable | 275.84K | 3.25M | 6.96M | 5.81M | 11.88M | 16.81M | 32.84M | 68.7M | 51.69M |
| Days Payables Outstanding | 26.54K | - | 165.49 | 95.97 | 116.1 | 46.91 | 63.7 | 91.67 | 25.18 |
| Short-Term Debt | 345.43K | 1.13M | 469K | 264K | 19K | 0 | 964K | 18.99M | 12.69M |
| Deferred Revenue (Current) | 0 | 3.64M | 0 | 3.23M | 6.14M | 4.94M | 10.99M | 11.25M | 39.02M |
| Other Current Liabilities | 847.17K | 3.38M | 2.72M | 7.65M | 14.12M | 47.33M | 85.7M | 109.67M | 87.81M |
| Current Ratio | 33.74x | 4.35x | 5.52x | 4.69x | 1.25x | 2.02x | 1.43x | 2.78x | 2.78x |
| Quick Ratio | 33.54x | 4.27x | 5.47x | 4.66x | 1.16x | 1.96x | 1.32x | 2.66x | 2.66x |
| Cash Conversion Cycle | - | - | 1.21K | 908.11 | 919.28 | 40.18 | 27.65 | 33.32 | 17.04 |
| Total Non-Current Liabilities | 332.49K | 15.56M | 21.25M | 64.49M | 68.19M | 92.88M | 91.98M | 617.31M | 469.43M |
| Long-Term Debt | 0 | 596.29K | 292K | 95K | 0 | 3.31M | 8.21M | 551.82M | 371.48M |
| Capital Lease Obligations | 0 | 0 | 1.35M | 1.34M | 1.91M | 6.49M | 7.68M | 8.14M | 49.94M |
| Deferred Tax Liabilities | 332.49K | 4.37M | 3.17M | 6.62M | 0 | 5.24M | 3.92M | 9.38M | 52.49M |
| Other Non-Current Liabilities | 0 | 10.59M | 16.44M | 57.41M | 43.23M | 55.31M | 60.02M | 44.67M | 201.99M |
| Total Liabilities | 1.8M | 23.8M | 31.88M | 78.81M | 106.17M | 175.35M | 249.39M | 948.22M | 768.01M |
| Total Debt | 345.43K | 1.73M | 2.13M | 2.21M | 2.54M | 10.45M | 17.45M | 581.45M | 418.25M |
| Net Debt | -48.41M | -24.04M | -42.47M | -75.74M | -19.5M | -105.88M | -105.79M | -128.9M | 211.1M |
| Debt / Equity | 0.01x | 0.03x | 0.03x | 0.03x | 1.18x | 0.13x | 0.12x | 1.02x | 1.02x |
| Debt / EBITDA | - | - | - | - | - | - | 0.30x | 6.62x | 3.16x |
| Net Debt / EBITDA | - | - | - | - | - | - | -1.80x | -1.47x | -1.47x |
| Interest Coverage | -677.34x | -540.52x | -16.72x | -41.92x | -429.88x | -226.43x | 3.83x | 3.83x | 4.31x |
| Total Equity | 49.29M▲ 0% | 52.9M▲ 7.3% | 70.08M▲ 32.5% | 79.02M▲ 12.7% | 2.16M▼ 97.3% | 80.01M▲ 3607.5% | 148.91M▲ 86.1% | 568.21M▲ 281.6% | 421.94M▲ 0% |
| Equity Growth % | - | 7.33% | 32.47% | 12.75% | -97.27% | 3607.46% | 86.12% | 281.58% | 803.3% |
| Book Value per Share | 0.39 | 0.26 | 0.30 | 0.31 | 0.01 | 0.26 | 0.46 | 1.65 | 1.25 |
| Total Shareholders' Equity | 49.29M | 52.9M | 70.08M | 79.02M | 2.16M | 80.01M | 148.91M | 568.21M | 421.94M |
| Common Stock | 55.56M | 72.05M | 115.94M | 167.06M | 170.84M | 370.97M | 446.27M | 596.78M | 0 |
| Retained Earnings | -6.38M | -20.21M | -48.07M | -92.96M | -173.47M | -272.81M | -263.67M | -212.96M | -150.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 109K | 1.06M | 2.21M | 4.92M | 4.79M | -18.15M | -33.69M | 184.4M | 99.81M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TLX Cash Flow Statement
Telix Pharmaceuticals Limited (TLX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.03M | -20.75M | -23.33M | 1.96M | -59.33M | -63.97M | 23.88M | 43.03M | 43.03M |
| Operating CF Margin % | - | -10632.77% | -669.53% | 37.6% | -781.04% | -39.96% | 4.75% | 5.49% | - |
| Operating CF Growth % | - | -244.01% | -12.45% | 108.4% | -3126.94% | -7.82% | 137.34% | 80.16% | 461.33% |
| Net Income | -6.38M | -13.83M | -27.87M | -44.89M | -80.51M | -104.08M | 5.21M | 49.92M | 65.97M |
| Depreciation & Amortization | 3.79K | 7K | 4.24M | 4.88M | 5.17M | 5.38M | 6.74M | 8.02M | 26.09M |
| Stock-Based Compensation | 109.02K | 712K | 1.27M | 2.35M | 1.32M | 8.11M | 8.79M | 19.66M | 44.63M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.12M | 1.06M | 2.37M | 40.23M | 22.1M | 55.26M | 60.68M | 64.26M | 96.48M |
| Working Capital Changes | -890.22K | -8.7M | -3.34M | -612K | -7.42M | -28.64M | -57.53M | -98.82M | -156.36M |
| Change in Receivables | -338.8K | -7.22M | -3.63M | -328K | -7.19M | -19.93M | -27.38M | -57.08M | -84.46M |
| Change in Inventory | 0 | 0 | 101K | -91K | -2.82M | -5.02M | -9.64M | -3.24M | -12.88M |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -1.26K | -2.69M | -468K | -1.09M | -2.73M | -17M | -25.49M | -135.17M | -550.86M |
| Capital Expenditures | -5.64K | 0 | -403K | -248K | -1.34M | -7.04M | -9.68M | -14.32M | -31.03M |
| CapEx % of Revenue | - | - | 11.56% | 4.76% | 17.63% | 4.4% | 1.93% | 1.83% | - |
| Acquisitions | 4.38K | -2.69M | 0 | -322K | 0 | -973K | -1.48M | -34.69M | -385.38M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -65K | -521K | -1.39M | -8.99M | -14.33M | -86.16M | -134.45M |
| Cash from Financing | 54.79M | -869K | 42.72M | 34.12M | 2.85M | 174.96M | 10.19M | 638.92M | 639.95M |
| Debt Issued (Net) | -769.18K | -869K | -1.17M | -904K | -936K | 1.74M | 3.53M | 652.81M | -3.97M |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 55.56M | 0 | 43.89M | 35.02M | 3.78M | 173.22M | 6.65M | -13.88M | 643.91M |
| Net Change in Cash | 54.79M▲ 0% | -22.99M▼ 142.0% | 18.83M▲ 181.9% | 33.35M▲ 77.1% | -55.91M▼ 267.7% | 94.29M▲ 268.7% | 6.91M▼ 92.7% | 587.11M▲ 8399.0% | 893.9M▲ 0% |
| Free Cash Flow | -6.04M▲ 0% | -20.75M▼ 243.7% | -23.74M▼ 14.4% | 1.71M▲ 107.2% | -60.67M▼ 3643.6% | -71.01M▼ 17.0% | 14.21M▲ 120.0% | 28.71M▲ 102.1% | 45.49M▲ 0% |
| FCF Margin % | - | -10632.77% | -681.09% | 32.84% | -798.67% | -44.35% | 2.83% | 3.67% | 2.74% |
| FCF Growth % | - | -243.69% | -14.4% | 107.21% | -3643.63% | -17.05% | 120% | 102.09% | 149.2% |
| FCF per Share | -0.05 | -0.10 | -0.10 | 0.01 | -0.21 | -0.23 | 0.04 | 0.08 | 0.08 |
| FCF Conversion (FCF/Net Income) | 0.95x | 1.50x | 0.84x | -0.04x | 0.74x | 0.61x | 4.58x | 0.86x | 0.69x |
| Interest Paid | 5.3K | 17K | 117K | 191K | 189K | 408K | 785K | 4.73M | 14.1M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TLX Key Ratios
Telix Pharmaceuticals Limited (TLX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -27.07% | -45.32% | -60.21% | -198.36% | -253.34% | 4.55% | 13.92% | 15.63% |
| Return on Invested Capital (ROIC) | -79.11% | -106.92% | -239.15% | - | - | 451.37% | 25.54% | 25.54% |
| Gross Margin | 100% | -340.75% | -323.75% | -391.85% | 18.32% | 62.56% | 65.08% | 61.64% |
| Net Margin | -7087.06% | -799.63% | -861.06% | -1059.9% | -65.01% | 1.04% | 6.37% | 3.98% |
| Debt / Equity | 0.03x | 0.03x | 0.03x | 1.18x | 0.13x | 0.12x | 1.02x | 1.02x |
| Interest Coverage | -540.52x | -16.72x | -41.92x | -429.88x | -226.43x | 3.83x | 3.83x | 4.31x |
| FCF Conversion | 1.50x | 0.84x | -0.04x | 0.74x | 0.61x | 4.58x | 0.86x | 0.69x |
| Revenue Growth | - | 1685.88% | 49.58% | 45.71% | 2007.64% | 213.9% | 55.85% | 329.97% |
TLX Frequently Asked Questions
Telix Pharmaceuticals Limited (TLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Telix Pharmaceuticals Limited (TLX) reported $1.66B in revenue for fiscal year 2024.
Telix Pharmaceuticals Limited (TLX) grew revenue by 55.8% over the past year. This is strong growth.
Yes, Telix Pharmaceuticals Limited (TLX) is profitable, generating $66.0M in net income for fiscal year 2024 (6.4% net margin).
Dividend & Returns
Telix Pharmaceuticals Limited (TLX) has a return on equity (ROE) of 13.9%. This is reasonable for most industries.
Telix Pharmaceuticals Limited (TLX) generated $45.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More TLX
Telix Pharmaceuticals Limited (TLX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates